Approval · Notice of Compliance 32837 · 2024
IBRANCE: Notice of Compliance 32837
Issued March 7, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32837
- Date
- March 7, 2024
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Expand the indication. Safety updates to the Product Monograph.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| IBRANCE | Not yet assigned | — |
Medicinal ingredients
- PALBOCICLIB 75 MG per TAB
- PALBOCICLIB 100 MG per TAB
- PALBOCICLIB 125 MG per TAB
- PALBOCICLIB 75 MG per CAP
- PALBOCICLIB 100 MG per CAP
- PALBOCICLIB 125 MG per CAP